Cargando…

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India

BACKGROUND: Elevated JAK2V617F allele burden is associated with enhanced expression of downstream target genes in Philadelphia negative chronic myeloproliferative neoplasms (CMPNs) which include PV, ET & PMF. Previous studies have shown the impact of JAK2V617F allele burden on clinical phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sazawal, Sudha, Singh, Kanwaljeet, Chhikara, Sunita, Chaubey, Rekha, Mahapatra, Manoranjan, Saxena, Renu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	ORIGINAL ARTICLE: Hematolymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498707/ https://www.ncbi.nlm.nih.gov/pubmed/31069197 http://dx.doi.org/10.4103/sajc.sajc_161_18

Ejemplares similares

Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib
por: Chhikara, Sunita, et al.
Publicado: (2018)

Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR–ABL1: A report of four cases from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes
por: Chaubey, Rekha, et al.
Publicado: (2011)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
por: Bjørn, M.E., et al.
Publicado: (2014)

Sigmoid Venous Thrombosis in JAK2 V617F Mutated Polycythemia Vera
por: Martins De Oliveira Filho, Cilomar, et al.
Publicado: (2022)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India
por: Suresh, Babu, et al.
Publicado: (2019)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Langerhans cell histiocytosis: An enigmatic disease
por: Jain, Anubha, et al.
Publicado: (2019)

Mutation profile in Indian primary myelofibrosis patients and its clinical implications
por: Patil, Vinod R., et al.
Publicado: (2019)

Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia
por: Chennamaneni, Rachana, et al.
Publicado: (2018)

Clinico-epidemiological features and response in childhood acute lymphoblastic leukemia at regional cancer center of Northeast India
por: Saikia, Bhargab Jyoti, et al.
Publicado: (2019)

JAK2 V617F-positive polycythemia vera accompanied by renal artery stenosis
por: Kim, Jae Young, et al.
Publicado: (2014)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
por: Kanduła, Zuzanna, et al.
Publicado: (2022)

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2016)

JAK2 Negative Polycythemia Vera
por: Geetha, J P, et al.
Publicado: (2010)

Cerebral venous sinus thrombosis in polycythemia vera patients with JAK2V617F mutation
por: Shen, Hui-Xin, et al.
Publicado: (2021)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2022)

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
por: Mori, Naoki, et al.
Publicado: (2023)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera
por: Lorenzo, Mariana, et al.
Publicado: (2020)

Hereditary hemochromatosis and JAK2‐positive polycythemia vera
por: Radwan, Ahmed, et al.
Publicado: (2021)

JAK2 and TET2 Mutation in Polycythemia Vera
por: Padda, Jaskamal, et al.
Publicado: (2021)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Thrombopoietin is required for full phenotype expression in a JAK2(V617F) transgenic mouse model of polycythemia vera
por: Spivak, Jerry L., et al.
Publicado: (2020)

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes
por: Sureau, Léa, et al.
Publicado: (2022)

Association of polycythemia vera with positive JAK2V617F mutation and myasthenia gravis: A report of two cases
por: Sasi, Sreethish, et al.
Publicado: (2020)

Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
por: Müller, Peter, et al.
Publicado: (2022)

Development and Inter-Laboratory Validation of Unlabeled Probe Melting Curve Analysis for Detection of JAK2 V617F Mutation in Polycythemia Vera
por: Wu, Zhiyuan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tko124m7cof81m4510j8bj802h